Probiotics for GI Health in 2012: Issues and Updates

Table 1. World Gastroenterology Organization (WGO)¹ and Yale Probiotic Working Group² Recommendations Regarding Probiotics Marketed in the United States: Uses for GI Conditions. Probiotic use is not recommended for seriously ill patients.

INDICATION	GENUS/SPECIES/ STRAIN	PATIENT POPULATION: STRENGTH OF EVIDENCE ^A / EFFECTIVENESS ^B (Evidence-based dose)	COMMERCIAL PRODUCT/ PROPRIETARY MICROBE NAME/ MANUFACTURER'S RECOMMENDED DOSE	MANUFACTURER'S WEBSITE	COST/QUANTITY ^c
Prevention of Acute Infectious Diarrhea	Lactobacillus rhamnosus (GG)	Pediatrics: B	Culturelle 10x10° CFU/ day To support digestive health and immune function 10x10° CFU twice per day for digestive upset	http://www.culturelle. com/	\$18.52/30 capsules (1 x 10 ¹⁰ CFU/capsule); \$15.82/30 powder packets (1.5 x10 ⁹ CFU/packet)
	Saccharomyces cerevisiae var. boulardii	Pediatrics: B	Florastor Saccharomyces boulardii (lyophilized [lyo]) 250 mg Contraindicated with central venous catheter	http://florastor.com/	\$35.50/50 capsules (250 mg/capsule); \$19/10 powder packets (250 mg/packet)
Treatment of Acute Infectious Diarrhea	Lactobacillus reuteri (DSM 17938)	Pediatrics: A (10 ⁸ CFU twice daily)	BioGaia Lactobacillus reuteri protectis 1x108 CFU/dose	http://www.childrenspro- biotics.com/	\$39.50/ 50 mL; \$25.39/ 30 chewable tablets; \$29.99/30 straws
	Lactobacillus rhamnosus (GG)	Pediatrics: 1a/A (10 ¹⁰ -10 ¹¹ CFU twice daily) Adults 2b (10 ⁹ CFU twice daily)	Culturelle 10x10³ CFU/ day To support digestive health and immune function Twice per day for digestive upset	http://www.culturelle. com/	\$18.52/30 capsules (1 x 1010 CFU/capsule); \$15.82/30 powder packets (1.5 x109 CFU/packet)
	Saccharomyces cerevisiae var. boulardii	Pediatrics: 1a/A (200 mg three times daily) Adults: 1b (10° CFU per capsule of 250 mg, 2-6 capsules per day)	Florastor Saccharomyces boulardii (Iyophilized [Iyo]) 250 mg Contraindicated with central venous catheter	http://florastor.com/	\$35.50/50 capsules (250 mg/capsule); \$19/10 powder packets (250 mg/packet)
Prevention of Antibiotic-associated Diarrhea	Lactobacillus acidophilus (CL1285) and Lactobacillus casei (LBC80R)	Adult: 1b (5x10 ¹⁰ CFU once or twice daily)	BioK+ Cultured food or capsules	https://www.biokplus. com/en-us/home	Capsules available \$12.00/15 capsules (12.5 x10° CFU/capsule); \$20.00/15 capsules (25 x10° CFU/capsule); \$31.50/15 capsules (50 x10° CFU/capsule)
	Lactobacillus casei (DN-114 001)	Adult: 1b/A (10 ¹⁰ CFU twice daily)	DanActive Lactobacillus immunitas Plus starter cultures Yogurt or cultured food ^d	http://www.dannon.com/ ourproducts.aspx	Price varies by store
	Lactobacillus rhamnosus (GG)	Pediatrics: 1b/A (10 ¹⁰ CFU once or twice daily) Adult: 1b (10 ¹⁰ - 10 ¹¹ CFU twice daily)	Culturelle 10x10° CFU/day To support digestive health and immune function 10x10° CFU/twice per day for digestive upset	http://www.culturelle. com/	\$18.52/30 capsules (1 x 10 ¹⁰ CFU/capsule); \$15.82/30 powder packets (1.5 x10 ⁹ CFU/packet)
	Saccharomyces cerevisiae var. boulardii	Pediatrics: 1a/A (250 mg twice daily) Adults: 1b (1 g or 4x10 ⁹ CFU daily)	Florastor Saccharomyces boulardii (lyophilized [lyo]) 250 mg Contraindicated with central venous catheter	http://florastor.com/	\$35.50/50 capsules (250 mg/capsule); \$19/10 powder packets (250 mg/packet)

Disclaimer: It is hoped that information in this activity will be useful in the management of your patients. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, review of any applicable manufacturers' product information, and comparison with recommendations of recognized authorities. The information in this activity is provided to medical professionals for information purposes only. It is NOT to be disseminated to patients or for any other purpose. In particular, no information contained within this activity is intended to be used for medical diagnosis or treatment.

Probiotics for GI Health in 2012: Issues and Updates

INDICATION	GENUS/SPECIES/ STRAIN	PATIENT POPULATION: STRENGTH OF EVIDENCE ^A / EFFECTIVENESS ^B (Evidence-based dose)	COMMERCIAL PRODUCT/ PROPRIETARY MICROBE NAME/ MANUFACTURER'S RECOMMENDED DOSE	MANUFACTURER'S WEBSITE	COST/QUANTITY ^c
Prevention of C. difficile diarrhea	Lactobacillus acidophilus (CL1285) and Lactobacillus casei (LBC80R)	Adult: 1b (5x10° CFU once or twice daily)	BioK+ Cultured food or capsules	https://www.biokplus. com/en-us/home	\$12.00/15 capsules (12.5 x10 ⁹ CFU/capsule); \$20.00/15 capsules (25 x10 ⁹ CFU/capsule); \$31.50/15 capsules (50 x10 ⁹ CFU/capsule)
	Lactobacillus casei (DN-114 001)	Adult: 1b (10 ¹⁰ CFU twice daily)	DanActive Lactobacillus immunitas Yogurt or cultured food ^d	http://www.dannon.com/ ourproducts.aspx	Price varies by store
	Lactobacillus rhamnosus (GG)	Adult: B/C	Culturelle 10x10° CFU/ day To support digestive health and immune function 10x10° CFU/ twice per day for digestive upset	http://www.culturelle. com/	\$18.52/30 capsules (1 x 10 ¹⁰ CFU/capsule); \$15.82/30 powder packets (1.5 x10 ⁹ CFU/packet)
	Saccharomyces cerevisiae var. boulardii	Adult: 1b/B/C (2-3 x10° CFU daily for 28 days, followed for another 4 weeks)	Florastor Saccharomyces boulardii (lyophilized [lyo]) 250 mg Contraindicated with central venous catheter	http://florastor.com/	\$35.50/50 capsules (250 mg/capsule); \$19/10 powder packets (250 mg/packet)
Inflammatory Bowel Diseases (IBD) Treatment of mildly active UC or pouchitis	Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, Streptococcus thermophilus	Pediatrics: 1b (4-9x10 ¹¹ CFU twice daily) Adults: 1b (2-9x10 ¹¹ CFU twice daily)	VSL#3 For use under the supervision of a physician (Strains not indicated on product)	http://www.vsl3.com/	Capsules that contain 112.5 billion live bacteria \$54/60 capsules (\$7.20/2x 9x10 ¹¹ CFU dose); Packets that contain 450 billion live bacteria \$86/30 packets (\$5.73/2x9x10 ¹¹ CFU dose); Double Strength (DS) packets that contain 900 billion live bacteria. Price not given
IBD Induction of remission IBD Prevention and maintenance of remission of pouchitis		Pouchitis: C UC: B Adults: 1b/A (9x10 ¹¹ CFU twice daily)			
IBD Maintenance of remission of ulcerative colitis		Adults: A			
Irritable Bowel Syndrome Symptomatic relief	Bifidobacterium infantis (35624)	Adults: 1b/B (10 ⁸ CFU once daily)	Align Bifantis 1x10 ⁹ CFU/ day As 1 capsule	http://www.aligngi.com/	\$44.99/42 capsules (\$1.07/capsule)
	Bifidobacterium animalis subsp. lactis (DN-173 010) + starter cultures	Adults: 1b/C (10 ¹⁰ CFU twice daily)	Activia Bifidobacterium regularis Yogurt ^d	http://activia.us.com/	Price varies by store
Pediatric functional bowel disorders- Symptomatic relief	Lactobacillus reuteri DSM 17938	Pediatrics: 1b (10 ⁸ CFU twice daily)	BioGaia Lactobacillus reuteri protectis 1x10 ⁸ CFU/dose	http://www.childrenspro- biotics.com/	\$39.50/50 mL (107 CFU/5 drops); \$25.39/30 chewable tablets (107 CFU/tablet); \$29.99/30 straws (107 CFU/straw)
	Lactobacillus rhamnosus (GG)	Pediatrics: 1a (10 ¹⁰ -10 ¹¹ CFU twice daily)	Culturelle 10x10 ⁹ CFU/day To support digestive health and immune function 10x10 ⁹ CFU twice per day for digestive upset	http://www.culturelle. com/	\$18.52/30 capsules (1 x 10 ¹⁰ CFU/capsule); \$15.82/30 powder packets (1.5 x10 ⁹ CFU/packet)

Disclaimer: It is hoped that information in this activity will be useful in the management of your patients. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients conditions, review of any applicable manufacturers' product information, and comparison with recommendations of recognized authorities. The information in this activity is provided to medical professionals for information purposes only. It is NOT to be disseminated to patients or for any other purpose. In particular, no information contained within this activity is intended to be used for medical diagnosis or treatment.

Probiotics for GI Health in 2012: Issues and Updates

aWorld Gastroenterology Organization (WGO) levels of evidence are defined as: 1a, systematic review with homogeneity of randomized controlled trials; 1b = individual randomized, controlled trial with narrow confidence interval; or 2b, individual cohort study, including low-quality RCT

Effectiveness ratings assigned by the Yale working group are defined as: A = strong, positive studies in the literature; B = based on positive controlled studies, but presence of some negative studies that did not support the primary outcome; C = some positive studies but clearly inadequate amount of work to establish certainty

^cPrices were taken from various websites for US distributors on August 16, 2012

dThe CFU/per serving is not available for some yogurts and fermented milk preparations. Patients may wish to try consuming 2 to 3 servings a day and adjust their dose as needed

¹Guarner F, Khan AG, Garisch J, et al. World Gastroenterology Organisation Global Guidelines: Probiotics and prebiotics, October 2011. *J Clin Gastroenterol*. 2012;46(6):468-481. Available at http://www.worldgastroenterology.org/assets/export/userfiles/Probiotics_FINAL_20110116.pdf.

²Floch MH, Walker WA, Madsen K, et al. Recommendations for probiotic use-2011 update. J Clin Gastroenterol. 2011;45 Suppl:S168-171.

Content Disclaimer: The authors are exclusively responsible for the respective content. Accordingly, no responsibility is assumed by the contributing faculty, educational grant providers, and Primary Care Network and its affiliates associated with this activity for any injury and/or damage to persons or property as a matter of product liability, negligence or otherwise; or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without medically appropriate (1) evaluation of (a) their patients' conditions and (b) indications and possible contraindications, warnings, and adverse effects or dangers in use; (2) review of any applicable manufacturers' prescribing and other product information; (3) comparison with recommendations of recognized authorities; and (4) independent verification of diagnostic methods, therapeutic methods, results of research, and measurement of medical doses.